MT-1207

MT-1207

Clinical data
Other names	MT1207; II-13
Drug class	Serotonin 5-HT2A receptor antagonist; α1-Adrenergic receptor antagonist; Calcium channel blocker
Pharmacokinetic data
Onset of action	0.5–1.25 hours (TmaxTooltip time to peak levels)[1]
Elimination half-life	4–7 hours[1]
Identifiers
IUPAC name 3-[4-[4-(benzotriazol-1-yl)butyl]piperazin-1-yl]-1,2-benzothiazole
CAS Number	1610793-69-5
PubChem CID	76283388
ChemSpider	129431460
UNII	YHJ29MGZ6G
ChEMBL	ChEMBL6070424
Chemical and physical data
Formula	C21H24N6S
Molar mass	392.53 g·mol^−1
3D model (JSmol)	Interactive image
SMILES C1CN(CCN1CCCCN2C3=CC=CC=C3N=N2)C4=NSC5=CC=CC=C54
InChI InChI=1S/C21H24N6S/c1-4-10-20-17(7-1)21(23-28-20)26-15-13-25(14-16-26)11-5-6-12-27-19-9-3-2-8-18(19)22-24-27/h1-4,7-10H,5-6,11-16H2 Key:GOALZWVIJQGFQJ-UHFFFAOYSA-N

MT-1207 is a combined serotonin 5-HT_2A receptor antagonist, α₁-adrenergic receptor antagonist, and calcium channel blocker which is under development for the treatment of hypertension (high blood pressure).^{[2][3][4][5][1]} It is taken orally.^[3] The drug's time to peak levels is 0.5 to 1.25 hours and its elimination half-life is 4 to 7 hours.^[1] MT-1207 is under development in China.^[3] As of 2025, MT-1207 has reached phase 2 clinical trials.^[2][3]

References

1. Zhang H, Wu M, Hu Y, Li C, Zheng W, Liu J, et al. (March 2021). "Pharmacokinetics and pharmacodynamics of MT-1207, a novel multitarget blocker of α1 receptor, 5-HT2A receptor, and calcium channel, in healthy subjects". Expert Opinion on Investigational Drugs. 30 (3): 271–278. doi:10.1080/13543784.2021.1887137. PMID 33560891.
2. "Delving into the Latest Updates on MT-1207 with Synapse". Synapse. 12 January 2026. Retrieved 18 January 2026.
3. "MT-1207 Drug Profile". Ozmosi. 1 January 1900. Retrieved 18 January 2026.
4. Wang P, Zhu H, Tian JS, Zhu W, Xu S, Yao H, et al. (September 2024). "Discovery of MT-1207: A Novel, Potent Multitarget Inhibitor as a Promising Clinical Candidate for the Treatment of Hypertension". Journal of Medicinal Chemistry. 67 (18): 16128–16144. doi:10.1021/acs.jmedchem.4c00626. PMID 38968440.
5. Xu TY, Wang P, Tian JS, Qing SL, Wang SN, Huang YH, et al. (June 2021). "Pharmacological characterization of MT-1207, a novel multitarget antihypertensive agent". Acta Pharmacologica Sinica. 42 (6): 885–897. doi:10.1038/s41401-021-00636-1. PMC 8149631. PMID 33782540.